1.78
1.14%
0.02
アフターアワーズ:
1.96
0.18
+10.11%
前日終値:
$1.76
開ける:
$1.9
24時間の取引高:
185.70K
Relative Volume:
4.87
時価総額:
$180.67M
収益:
$5.15M
当期純損益:
$-65.35M
株価収益率:
-0.8945
EPS:
-1.99
ネットキャッシュフロー:
$-20.85M
1週間 パフォーマンス:
-2.73%
1か月 パフォーマンス:
-6.02%
6か月 パフォーマンス:
-40.47%
1年 パフォーマンス:
-37.76%
Cellectis Adr Stock (CLLS) Company Profile
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-03-17 | 開始されました | Bryan Garnier | Buy |
2022-05-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
2022-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
2021-11-08 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-10-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2021-04-28 | ダウングレード | Guggenheim | Buy → Neutral |
2021-03-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
2020-08-19 | アップグレード | Citigroup | Neutral → Buy |
2020-05-12 | 開始されました | Robert W. Baird | Outperform |
2020-03-06 | ダウングレード | Goldman | Neutral → Sell |
2019-10-30 | 再開されました | Guggenheim | Buy |
2019-08-09 | 開始されました | BTIG Research | Buy |
2019-05-24 | 再開されました | Citigroup | Neutral |
2019-03-14 | 開始されました | William Blair | Outperform |
2018-12-19 | 開始されました | Goldman | Neutral |
2018-07-16 | 開始されました | Barclays | Overweight |
2018-03-16 | 開始されました | Guggenheim | Neutral |
2017-09-05 | ダウングレード | SunTrust | Buy → Hold |
2017-09-05 | 繰り返されました | Wells Fargo | Outperform |
2017-03-02 | 開始されました | Instinet | Buy |
2017-02-28 | 開始されました | Wells Fargo | Outperform |
2016-04-05 | 開始されました | Ladenburg Thalmann | Buy |
2016-03-02 | 開始されました | Sun Trust Rbsn Humphrey | Buy |
2015-07-20 | 開始されました | BofA/Merrill | Buy |
2015-04-20 | 開始されました | Jefferies | Buy |
2015-04-20 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Cellectis Adr (CLLS) 最新ニュース
Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com
Cellectis earnings missed by $0.03, revenue topped estimates - Investing.com
Cellectis stock touches 52-week low at $1.77 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges - Investing.com
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges By Investing.com - Investing.com South Africa
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
A year in review: Cellectis ADR (CLLS)’s performance in the last year - US Post News
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Market Insights: Cellectis ADR (CLLS)'s Notable Drop of -5.84, Closing at 2.02 – DWinneX - The Dwinnex
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - The Globe and Mail
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results - The Globe and Mail
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results - Investing.com India
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results By Investing.com - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower - MSN
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By Investing.com - Investing.com India
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca - Investing.com India
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall Again in Tuesday Trading - MSN
CellectisADR (CLLS) Price Target Increased by 20.85% to 11.75 - MSN
There's a Lot of Upside For Emerging Gene-Editing Companies - The Globe and Mail
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature.com
Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger - Equities News
Cellectis Completes Sale of $47 million through its ATM program - The Globe and Mail
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq - The Globe and Mail
Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U
Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance
30 Stocks Moving In Wednesday's Pre-Market SessionAdtran Holdings (NASDAQ:ADTN), Adient (NYSE:ADNT) - Benzinga
7 Gene Editing Companies Investors Should Watch - Nanalyze
25 Stocks Moving In Tuesday's Pre-Market SessionBioCryst Pharma (NASDAQ:BCRX) - Benzinga
25 Stocks Moving In Monday's Pre-Market SessionAltisource Portfolio (NASDAQ:ASPS) - Benzinga
Top 10 Luxury Car Brands In The World - Insider Monkey
Cellectis (CLLS) Stock Price, News & AnalysisNASDAQ - MarketBeat
15 Biotechs Making Announcements At The 2015 Piper Jaffray Healthcare ConferenceAbeona Therapeutics (N - Benzinga
Morning Market GainersCellectis (NASDAQ:CLLS) - Benzinga
New Strong Buy Stocks for October 27th - Nasdaq
BofA Starts Cellectis At Buy, Sees Plant Sciences As 'Hidden Gem'Cellectis (NASDAQ:CLLS) - Benzinga
Cellectis Adr (CLLS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):